ZIOPHARM Presents Positive Palifosfamide Sarcoma Randomized Phase II Interim Data At Annual Meeting Of The Connective Tissue Oncology Society

ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) presented today at the 15th Annual Connective Tissue Oncology Society (CTOS) Meeting, positive interim data from the multicenter randomized Phase II trial of palifosfamide (ZymafosTM, ZIO-201) treating patients with unresectable or metastatic soft tissue sarcoma.

Go to Source

People who read this also read

• Immune Thrombocytopenia in Patients with Connective Tissue Disorders and the Antiphospholipid Antibody Syndrome
  It has been theorized that immune thrombocytopenia (ITP) is a syndrome characterized by various defects in immune regulation, resulting in a common phenotype, decreased blood platelets, and symptoms of mucocutaneous bleeding. Most often, successful treatment of the underlying connective tissue disor...
• BioVex Announces Publication Of Phase 2 Melanoma Results With OncoVEX (GM-CSF) In The Journal Of Clinical Oncology
  BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced that the data from its completed Phase 2 clinical study of OncoVEX (GM-CSF) for the treatment of advanced melanoma has been published in the Journal of Clinical Onco...
• Prometheus And Bayer Schering Pharma To Apply Novel Diagnostic Platform To Oncology Therapeutic Candidates
  Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced the execution of a research collaboration and license agreement with Bayer Schering Pharma AG, Germany, a worldwide leading specialty pharmaceutical company. The collaboration partners Prometheus' proprietary ...
• Celsion Corporation Announces ThermoDox(R) Abstract Accepted For Presentation At The American Society Of Clinical Oncology 2010 Annual Meeting
  Celsion Corporation ( CLSN) announced that an abstract about the Phase I/II trial of ThermoDox® in Recurrent Chest Wall Cancer (RCW) has been accepted for presentation at the American Society of Clinical Oncology (ASCO) 2010 Annual Meeting. The abstract presents the background, rationale, and desig...
• ESMO Conference On Sarcoma And GIST: Spotlight On Rare Tumors In Hunt For New Cancer Treatments
  New breakthrough treatments for the most common cancers could soon come from cutting-edge research into some of the world's rarest tumors. At the ESMO Conference on Sarcoma and GIST, to be held in Milan, Italy, on 9 and 10 March 2010, researchers and some of the world's leading experts will discuss ...